Durata Therapeutics, Inc. (DRTX) Reports First Quarter 2013 Financial Results
5/9/2013 10:00:44 AM
More...
|
Durata Therapeutics, Inc. (DRTX) to Present at Bank of America (BAC) Merrill Lynch 2013 Healthcare Conference
5/7/2013 9:04:25 AM
More...
|
Durata Therapeutics, Inc. (DRTX) Release: Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting
4/29/2013 11:43:09 AM
More...
|
Durata Therapeutics, Inc. (DRTX) Release: New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID Meeting
4/29/2013 11:38:45 AM
More...
|
Durata Therapeutics, Inc. (DRTX) Reports Full-Year 2012 Financial Results
3/8/2013 10:11:59 AM
More...
|
Durata Therapeutics, Inc. (DRTX) Sees Positive Results From Dalbavancin Study
2/25/2013 7:47:27 AM
More...
|
Durata Therapeutics, Inc. (DRTX) Says Skin Infection Drug Meets Late-Stage Trial Goal
1/4/2013 7:23:58 AM
More...
|
Durata Therapeutics, Inc. to Host Conference Call and Webcast on December 11, 2012 at 9:00AM ET to Present Preliminary Top-Line Results From Its DISCOVER 1 Study
12/11/2012 11:09:51 AM
More...
|
Durata Therapeutics, Inc. Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
12/11/2012 10:41:07 AM
More...
|
Durata Therapeutics, Inc. to Move HQs, Aims to Create 100 New Jobs
11/14/2012 8:29:05 AM
More...
|
|